Karan Chand Mohan Singh Saravanasingh, Shiny Ethel, J Jayalakshmi, I Nithyamala, G Chenthamarai Selvi
Department of Maruthuvam, National Institute of Siddha, Chennai, IND.
Department of Gunapadam, National Institute of Siddha, Chennai, IND.
Cureus. 2025 Jul 11;17(7):e87732. doi: 10.7759/cureus.87732. eCollection 2025 Jul.
Psoriasis is a chronic inflammatory disease causing a significant impact on quality of life. We report a 57-year-old male with moderate-to-severe plaque psoriasis (Psoriasis Area and Severity Index (PASI) 18.6, body surface area (BSA) 22%, Dermatology Life Quality Index (DLQI) 24, pruritus 9/10), intolerant of methotrexate. Under dermatology supervision, he underwent 12 weeks of Siddha therapy (Siddha topical herbal oil (()) + Siddha oral powder ( ())) with serial lab monitoring. Significant improvement was observed (PASI 2.4, BSA 3%, DLQI 3, pruritus 0/10), sustained at nine-month follow-up with no adverse effects. This real-world case highlights how patients can explore complementary medicine options, especially with the support of clinical supervision, and in this case, the results were quite positive. Serial photographs documented the significant resolution of plaques, although some residual post-inflammatory dyschromia remained. However, it is crucial to remember that guideline-directed therapy continues to be the cornerstone of psoriasis treatment. This uncontrolled, single-case observation does not establish Siddha therapy as a primary treatment or a valid alternative to evidence-based medicine. Instead, these findings should be viewed as preliminary data that require thorough validation. Further research, particularly randomized controlled trials that utilize standardized Siddha formulations, is essential to explore its potential role as a complementary approach within the established framework of evidence-based medicine, rather than as a replacement. Clinicians should continue prioritizing established guideline therapies while actively engaging patients in shared decision-making about complementary options.
银屑病是一种慢性炎症性疾病,对生活质量有重大影响。我们报告了一名57岁男性,患有中度至重度斑块状银屑病(银屑病面积和严重程度指数(PASI)为18.6,体表面积(BSA)为22%,皮肤病生活质量指数(DLQI)为24,瘙痒程度为9/10),不耐受甲氨蝶呤。在皮肤科监督下,他接受了12周的悉达疗法(悉达外用草药油(())+悉达口服散剂(())),并进行了系列实验室监测。观察到显著改善(PASI为2.4,BSA为3%,DLQI为3,瘙痒程度为0/10),在9个月的随访中持续存在,且无不良反应。这个真实病例突出了患者如何探索补充医学选择,特别是在临床监督的支持下,在这个病例中,结果相当积极。系列照片记录了斑块的显著消退,尽管仍有一些残留的炎症后色素沉着。然而,重要的是要记住,指南指导的治疗仍然是银屑病治疗的基石。这种非对照的单病例观察并不能将悉达疗法确立为主要治疗方法或循证医学的有效替代方法。相反,这些发现应被视为需要彻底验证的初步数据。进一步的研究,特别是利用标准化悉达制剂的随机对照试验,对于探索其在既定循证医学框架内作为补充方法的潜在作用至关重要,而不是作为替代方法。临床医生应继续优先考虑既定的指南疗法,同时积极让患者参与关于补充选择的共同决策。